UBS Increases Price Target for Merck (MRK) in Sector Preview

UBS raised its price target for Merck (MRK) to $145 from $130, maintaining a Buy rating as part of its Q1 pharmaceuticals and biotechnology sector preview. The move follows Merck's announcement of a tender offer to acquire Terns Pharmaceuticals for $53 per share.

By Vardah Gill Fri, April 17, 2026 at 8:54 PM GMT+3 1 min read · Yahoo Finance · April 17, 2026, 17:54 UTC

UBS Increases Price Target for Merck (MRK) in Sector Preview

Tickers: $MRK $TERN

Topics: dividend stocks merger and acquisition pharmaceuticals price target stock analysis

Read the full article at Yahoo Finance

More World news

Broadcom and Micron Identified as Top Alternatives to Nvidia Amid Leadership Uncertainty Motley Fool · November 12, 2026, 16:03 UTC
Thomson Reuters Executives to Present at TD Securities Technology Conference PR Newswire · November 12, 2026, 16:00 UTC
BHP to Restructure Australian Iron Ore Operations Amid Rising Costs Seeking Alpha · November 12, 2026, 15:59 UTC
Capri Investment Group and GRIT Chicago Unveil $10 Billion Bronzeville Lakefront Development Plan PR Newswire · November 12, 2026, 16:00 UTC
Whoop Launches 'Whoop Humans' Social Network to Enhance Health Data Sharing TechCrunch · November 12, 2026, 16:00 UTC
SchoolWise Partners Advises on Sale of Wyalusing Valley and Wysox Children's Centers PR Newswire · November 12, 2026, 15:57 UTC
Jensen Huang Resigns as Nvidia CEO Amid Personal Scandal and Leadership Crisis CNBC · November 12, 2026, 15:45 UTC
Keurig Dr Pepper Launches $2 Billion Equity Offering to Reduce Debt Ahead of Corporate Split Seeking Alpha · November 12, 2026, 15:51 UTC
Old National Bancorp Announces Quarterly Dividend of $0.4375 per Share Seeking Alpha · November 12, 2026, 15:53 UTC
Old National Bancorp Announces Quarterly Dividend of $0.4375 per Share Seeking Alpha · November 12, 2026, 15:53 UTC